Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
limosilactobacillus reuteri AMBV339
- Development stage
- Unknown
- Lead developer
- DSM-Firmenich
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Limosilactobacillus reuteri* AMBV339 is a specific probiotic strain of the species *Limosilactobacillus reuteri* (formerly *Lactobacillus reuteri*) that has been characterized as a riboflavin (Vitamin B2) overproducer. Developed as part of the Humiome microbiome platform by DSM-Firmenich in collaboration with academic partners such as the University of Antwerp, the strain is designed to modulate the gut and vaginal microbiomes. By overproducing riboflavin, AMBV339 aims to increase the local availability of this essential nutrient in the distal intestine and vaginal environment, thereby supporting the growth of beneficial commensal bacteria and improving microbial health. It has been investigated in clinical trials (e.g., the VIAB2L project) both as a standalone intervention and in combination with colon-delivered riboflavin (Humiome B2) to assess its impact on microbial colonization and metabolomic profiles in healthy adult women.
- Other names
- Limosilactobacillus reuteri AMBV339L. reuteri AMBV339
Beyond the preview
Go deeper on limosilactobacillus reuteri AMBV339.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on limosilactobacillus reuteri AMBV339.